Frederic Chereau Appointed Pervasis President and CEO
Frederic Chereau has been named president and chief executive officer of Pervasis Therapeutics, Inc. (Cambridge, MA).
Frederic Chereau has been named president and chief executive officer of Pervasis Therapeutics, Inc. (Cambridge, MA). Chereau was formerly the vice president and general manager of Genzyme Cardiovascular (CV), a business unit within Genzyme Corporation. Under Chereau’s leadership, Genzyme CV expanded its cell and gene therapy programs and initiated research and commercial efforts in new markets. He was responsible for launching and commercializing a hypercholesterolemia product (Cholestagel–colesevelam) outside the US and oversaw the company’s late clinical stage gene therapy program in peripheral arterial disease and various earlier-stage programs.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
